Loading...
•
Sep 30, 2021
Agios Q3 2021 Earnings Report
Reported business highlights and financial results for the third quarter ended Sept. 30, 2021.
Key Takeaways
Agios Pharmaceuticals reported a net loss of $88.8 million for the third quarter of 2021, compared to a net loss of $99.0 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities were $1.4 billion as of Sept. 30, 2021.
Received FDA Priority Review designation for mitapivat in PK deficiency.
Initiated first global trial sites for Phase 3 ENERGIZE and ENERGIZE-T studies of mitapivat in thalassemia.
Continued start-up activities for the Phase 2/3 study of mitapivat in sickle cell disease.
Repurchased approximately 5.3 million shares of Agios common stock at an average price of $47.94 per share in Q3.
Forward Guidance
Agios expects that its cash, cash equivalents and marketable securities will enable the company to execute its operating plan through major catalysts and to cash-flow positivity without the need to raise additional equity.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...